William C. Hahn

Chief Scientific Officer Chair, Executive Committee for Research (ECR) at Dana-Farber Cancer Institute, Inc.

William C. Hahn

William C. Hahn

Chief Scientific Officer Chair, Executive Committee for Research (ECR) at Dana-Farber Cancer Institute, Inc.

Overview
Career Highlights

KSQ Therapeutics, Inc.

RelSci Relationships

3259

Number of Boards

6

Contact Data
Trying to get in touch with William C. Hahn? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals William C. Hahn likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director-Center for Sarcoma & Bone Oncology at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Pediatric Hematology/Oncology at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Director, Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chief, Division of Women's Cancers at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Director, the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chief Medical Officer & Medical Director, Adult Ambulatory Oncology at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Director, Center for Cancer Genetics & Prevention at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chair of Faculty at The Broad Institute, Inc.

Relationship likelihood: Strong

Paths to William C. Hahn
Potential Connections via
Relationship Science
You
William C. Hahn
Chief Scientific Officer Chair, Executive Committee for Research (ECR) at Dana-Farber Cancer Institute, Inc.
Education
PhD in Immunology

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

AB in Biochemical Science

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Memberships
Member
Current

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Career History
Scientific Co-Founder
2015 - Current

KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA.

Chief Scientific Officer Chair, Executive Committee for Research (ECR)
1996 - Current

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Professor of Medicine
Current

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Boards & Committees
Member, Scientific Advisory Board
Current

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Investments
Details Hidden

KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by William C. Hahn. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of William C. Hahn's profile does not indicate a business or promotional relationship of any kind between RelSci and William C. Hahn.